Piper Sandler reissued their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $105.00 price objective on the stock. Several other equities research analysts have also issued reports on the stock. Wedbush reaffirmed an outperform rating and issued a $86.00 price […]
Keros Therapeutics (NASDAQ:KROS) Given Outperform Rating at Wedbush theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics (NASDAQ:KROS) Reaches New 52-Week High at $68 50 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Wells Fargo & Company assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $60.00 target price on the stock. Separately, Wedbush reiterated an outperform rating and issued a $86.00 price objective on shares […]
Keros Therapeutics, Inc (NASDAQ:KROS) Given Consensus Rating of Buy by Analysts etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.